Board of Directors

Dr. Jutta Heim, Board member

Jutta Heim worked for more than 20 years at Ciba-Geigy/Novartis (CH and US). At Novartis, she was involved in the successful development and launch of anti-thrombotic and fibrinolytic products. She established Novartis’ molecular genetics department in oncology, became Novartis’ Senior Scientific Expert in Molecular Biology and a member of the Research Management Board. Jutta completed her career at Novartis heading the Novartis Lead Discovery Center with worldwide responsibility.

From 2004 to 2009, Jutta served as CSO at Basilea Pharmaceutica Ltd. a Swiss biopharmaceutical company focusing on anti-infectives, inflammation and oncology. From 2009 to 2013, she served as CTO and CSO at Evolva SA, where she led Evolva’s discovery activities and strengthened the development of its technology platform.

Jutta is a member of the advisory board of ‘‘Stiftung für Wissenschaftliche Forschung Universität Zürich’’, a board member of Evolva SA and chairs the scientific advisory committee of DNDi/GARDP, a not-for-profit organisation on antimicrobial resistance.

Jutta received a Ph.D. from the University of Tübingen in 1981 and holds a professorship in Biotechnology at the Biocenter of the University of Basel.

Dr. Morten Sommer, Board Member

Morten Sommer is the CSO of UNION and a co-founder of several biotech companies working within fields of drug development, industrial biotechnology and microbiome research.

Morten is also a Professor and Scientific Director at the Technical University of Denmark with a lab of 20+ Ph.Ds and Post-Doctorial researchers working primarily in the field of antibiotic resistance and the human microbiome. Morten is the inventor on 20+ issued patents, patent applications and author of scientific papers in journals such as Science, Cell and Nature and was named Top 10 under 40 on Genetic Engineering and Biotechnology News list of Biopharma Research and Business executives.

Morten holds a M.Sc. in Physics from University of Copenhagen and a Ph.D. in Biophysics from Harvard University from the laboratory of Professor George Church.

Ole Skov, Chairman of the Board

Ole has more than 30 years of experience in management and entrepreneurship. Since 2008, Mr. Skov has been an Independent Investor and recently entered into an investment partnership with the European Investment Fund. Previously Mr. Skov has been a Management Consultant at McKinsey & Co. from 1987-1994 and subsequently became Managing Partner at Accenture Financial Services from 1994-2007. Ole Skov is an investor and board member in several companies including Adsidius and Clinical-Microbiomics.

Ole holds a degree in Commerce from Copenhagen Business School and an MBA from IMD in Lausanne, Switzerland.

Dr. Rasmus Toft-Kehler, Board Member

Rasmus Toft-Kehler is the co-founder and board member of multiple biotech companies in the fields of microbiome research, immunology, and antibiotic resistance. Prior to entering biotech, Rasmus worked in leading investment banks and in management consulting, and as a board member of a family-owned enterprise that was sold in 2005.

Rasmus is the inventor of 5+ patents and has published research in leading entrepreneurship and scientific journals such as Journal of Business Venturing and Nature Reviews Microbiology.

Rasmus holds a Ph.D. in entrepreneurship from Copenhagen Business School with research stays at New York University and University of Cambridge as well as Harvard Business School.

In 2007, Rasmus led a team of four inexperienced sailors to successfully cross the Pacific Ocean.

Stig Løkke Pedersen, Board Member

Stig Løkke Pedersen serves as the chairman of the Board of Directors in NGI A/S, SSI Diagnostica A/S, Moksha8 Ltd, Transmedica A/S and Nuevolution AB. He is a member of the Board of Directors in MSI Methylation Sciences Inc, Skybrands A/S, BroenLab A/S and Index Pharmaceuticals AB. Stig is furthermore operating partner in the private equity fund Catacap A/S.

Stig served as Executive Vice President of Commercial Operations at H. Lundbeck A/S, heading all business activities in the Group from 2005 to 2011. He joined Lundbeck in 1992 and has served as Director of Business Development, Director of Corporate Affairs and Managing Director of Lundbeck's subsidiary in the Netherlands from 1992 to 1998. In 1998, he became Senior Vice President of Corporate Affairs, where he was responsible for the three product deals, transforming Lundbeck into a global player, namely Lexapro/Cipralex (escitalopram), Ebixa (memantine) and Azilect (rasagiline). In 2001, Stig obtained Operations in America, Asia and Africa. In 2003, he was appointed member of Lundbeck’s Board of Management. Stig worked for Ciba-Geigy 1986-1992 in Denmark, Switzerland and South Africa.
Stig holds a Masters in Economics from Aalborg University

 

Learn more